Replies to post #193140 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

It's very likely that Anavex is working with the Aussie healthcare system and data to define EEG/ERP parameters for 21st century diagnosis.

Population based screening methods are needed.

Box 2.1: Criteria for an effective population-based screening program
A screening program must meet certain criteria before it can be considered useful. Important factors
influencing the usefulness of a screening program include disease factors, testing factors and therapeutic
factors.
The disease being screened for must:
1. occur in an asymptomatic phase that lasts for a significant length of time
2. represent a significant burden to the population
3. lead to a bad outcome if left untreated.
A screening test must be available that is:
1. able to detect the disease during the asymptomatic phase
2. acceptable to patients and practitioners
3. cost-effective
4. highly sensitive and reasonably specific for the target disease.
In addition, there must be value in identifying the disease in the asymptomatic phase, that is:
1. There must be an effective treatment available that can cure or improve the outcome.
2. The outcome for the disease must be better if the treatment is applied during the asymptomatic period
than later in the course of the disease. Ideally there should be a chance for cure if treatment is given at an
early stage of disease.
Source: Adapted from IAM 2006.

https://www.aihw.gov.au/getmedia/17c4aac2-22d0-4d95-9346-41124a400504/dandad-c01.pdf.aspx

First discussed here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148695223

• The condition should be an important health problem
• The natural history of the condition should be understood
• There should be a recognisable latent or early symptomatic stage
• There should be a test that is easy to perform and interpret, acceptable,
accurate, reliable, sensitive and specific
• There should be an accepted treatment recognised for the disease
• Treatment should be more effective if started early
• There should be a policy on who should be treated
• Diagnosis and treatment should be cost-effective
• Case-finding should be a continuous process

The above is from a 2016 paper outlining the need for better screening and biomarkers in dementia:
https://onlinelibrary.wiley.com/doi/pdf/10.1002/pnp.410

[tradeherpete]

Not to be a spoil sport, but just nothing that EEG/ERP is not part of the outcome measures in any of the current trials and only figured in the early part of the P2a AD trial.

I can't really argue that.

However nidan was referencing current and future trials talking about leading the way. My reference to “the new trials” was speaking more to that as nidan’s contention is that Anavex is bringing more to the table than getting an approval. He is saying Anavex trials are the prototype for the redesign of how things will be done. And he is also saying, if I hear him right that, there can be no going back. Which implies this is happening.